How should I initially manage a patient with hemolytic‑uremic syndrome, both typical (diarrhea‑associated) and atypical forms?

Initial Management of Hemolytic Uremic Syndrome

Immediate Recognition and Stabilization

For any patient presenting with the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure, treat this as a medical emergency requiring immediate multidisciplinary consultation and urgent diagnostic workup to differentiate typical (diarrhea-associated) from atypical HUS, as management differs fundamentally between these forms. 1, 2

Critical First Actions

• Obtain urgent hematology and nephrology consultation immediately, as delays in identification are associated with increased mortality and morbidity 2, 3
• Stabilize any critical organ dysfunction including respiratory support, hemodynamic stabilization, and management of severe hypertension 1, 2
• Admit to intensive care unit if patient presents with severe thrombocytopenia (platelets <20,000/mm³), altered mental status, seizures, severe hypertension, or oliguria/anuria 1, 2

Urgent Diagnostic Workup

Essential Laboratory Tests (Obtain Within 1-2 Hours)

• Complete blood count with peripheral smear to identify schistocytes (>1% threshold), thrombocytopenia (<150,000/mm³), and anemia 2, 3, 4
• Hemolysis markers: elevated LDH, reduced or absent haptoglobin, elevated indirect bilirubin, elevated reticulocyte count 2, 3, 4
• Direct and indirect Coombs tests (must be negative to confirm non-immune hemolysis) 2, 4
• Renal function panel: serum creatinine, BUN, electrolytes, urinalysis for hematuria and proteinuria 2, 3, 4
• ADAMTS13 activity level urgently to exclude thrombotic thrombocytopenic purpura (TTP); activity <10% indicates TTP requiring immediate plasma exchange rather than HUS management 2, 3, 5

Differential Diagnosis Testing

• Stool culture and Shiga toxin testing (including E. coli O157:H7) to identify typical STEC-HUS 2, 3, 4
• Complement studies: C3, C4, CH50, and AP50 to assess complement pathway activation in suspected atypical HUS 2, 3, 4
• Coagulation studies: PT, aPTT, fibrinogen, D-dimer to exclude disseminated intravascular coagulation 2
• Blood cultures and viral studies (CMV, EBV, HHV6) if infection-triggered aHUS is suspected 2

Common Pitfall: Do not delay ADAMTS13 testing, as TTP requires immediate plasma exchange and has a fundamentally different treatment approach than HUS. Each hour of delay in TTP treatment increases mortality. 5

Management Based on HUS Type

Typical (Diarrhea-Associated) HUS Management

Typical HUS is managed with supportive care only; there is no role for plasma exchange, complement inhibitors, or antibiotics in the acute phase. 6, 7, 8

Supportive Measures for Typical HUS

• Parenteral volume expansion with isotonic crystalloids to counteract thrombotic microangiopathy and attenuate renal injury; target euvolemia 9
• Transfuse red blood cells only for symptomatic anemia or hemoglobin <7-8 g/dL in stable patients; use minimum units necessary 3
• Avoid platelet transfusions unless life-threatening bleeding occurs, as they can worsen microangiopathic thrombosis 3
• Provide folic acid 1 mg daily to support erythropoiesis during hemolysis 3
• Initiate renal replacement therapy (hemodialysis or peritoneal dialysis) for severe uremia, hyperkalemia, volume overload, or metabolic acidosis 7, 9
• Manage hypertension aggressively with antihypertensive medications to prevent hypertensive encephalopathy 9

Critical Medications to AVOID in Typical HUS

• Do NOT use antibiotics during acute diarrheal illness or established HUS, as they may increase Shiga toxin release and worsen outcomes 9
• Do NOT use antimotility agents (loperamide, diphenoxylate) as they prolong toxin exposure 9
• Do NOT use NSAIDs as they worsen renal perfusion 9
• Do NOT perform plasma exchange in typical STEC-HUS, as it provides no benefit and adds procedural risk 2, 7

Atypical HUS Management

For atypical HUS, initiate complement inhibition with eculizumab or ravulizumab within 4-8 hours of clinical diagnosis without waiting for genetic test results, as treatment delays are associated with increased morbidity and mortality. 3, 10

Immediate Complement Inhibitor Therapy

• Eculizumab dosing for adults: 900 mg IV weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter 3, 10
• Ravulizumab is an alternative with equivalent efficacy but longer duration allowing less frequent dosing 3
• Do NOT delay treatment for genetic testing results, as only 50-60% of aHUS cases have identifiable complement mutations 3, 4

Mandatory Vaccination and Prophylaxis (BEFORE Complement Inhibition)

Life-threatening meningococcal infections are the most serious risk of complement inhibitor therapy. 10

• Administer both meningococcal vaccines at least 2 weeks before starting eculizumab: quadrivalent conjugate vaccine (serogroups A, C, W, Y) AND serogroup B vaccine 3, 10
• If urgent therapy cannot be delayed for vaccination, administer vaccines immediately and provide continuous antibiotic prophylaxis with penicillin (or macrolide if penicillin-allergic) for the entire duration of complement inhibitor therapy 3, 10
• Continue antibiotic prophylaxis lifelong during complement inhibitor treatment 3
• Monitor continuously for signs of meningococcal infection (fever, headache, neck stiffness, altered mental status, rash) and evaluate immediately if suspected 10

Supportive Care for Atypical HUS

• Red blood cell transfusion according to same guidelines as typical HUS (hemoglobin <7-8 g/dL or symptomatic) 3
• Avoid platelet transfusions unless life-threatening bleeding; discuss with blood bank that patient has complement-mediated TMA before any transfusions 3
• Renal replacement therapy as needed for uremia, hyperkalemia, or volume overload 7, 11
• Hypertension management with antihypertensive medications 9

Monitoring During Acute Phase

Daily Laboratory Monitoring (Days 1-14)

• Hemoglobin and platelet counts to assess hematologic response; target platelet count >150,000/mm³ or avoid >25% reduction from baseline 3, 4
• LDH, haptoglobin, indirect bilirubin to monitor ongoing hemolysis 3, 4
• Serum creatinine, BUN, electrolytes to assess renal function 3, 4
• Urinalysis for hematuria and proteinuria to detect renal involvement 3

Clinical Monitoring

• Neurological examination at least twice daily, as 10-20% of aHUS patients develop neurologic complications (confusion, seizures, stroke) 4
• Obtain brain MRI and EEG if any neurological symptoms develop 2, 4
• Monitor for signs of meningococcal infection in patients receiving complement inhibitors 10

Duration of Treatment

Typical HUS

• Supportive care continues until hematologic parameters normalize and renal function stabilizes or recovers 6, 7
• Most pediatric cases recover within 2-3 weeks, though long-term renal sequelae occur in 30-50% due to nephron loss 6

Atypical HUS

• Eculizumab treatment should continue for at least 6 months initially 3
• Genetic risk stratification guides long-term treatment decisions; absence of identified mutations does NOT guarantee low recurrence risk 3
• Discontinuation requires careful monitoring for disease recurrence with serial complement levels, platelet counts, LDH, and renal function 3, 4

Critical Pitfalls to Avoid

• Do NOT start eculizumab without laboratory-confirmed active thrombotic microangiopathy (full triad of hemolysis, thrombocytopenia, and renal injury), as unnecessary complement inhibition carries serious meningococcal infection risk 3, 4
• Do NOT use plasma exchange for typical STEC-HUS, as it offers no benefit and adds procedural complications 2, 7
• Do NOT administer antibiotics during acute diarrheal illness when STEC-HUS is suspected, as this may worsen outcomes 9
• Do NOT delay ADAMTS13 testing, as TTP requires immediate plasma exchange rather than HUS management 2, 5
• Do NOT transfuse platelets prophylactically in either typical or atypical HUS, as this can worsen microangiopathic thrombosis 3
• Do NOT wait for genetic test results before starting complement inhibition in suspected aHUS, as 40-50% have no identifiable mutation and treatment delays increase mortality 3, 4